Oliceridine for the Management of Moderate to Severe Acute Postoperative Pain: A Narrative Review
Neil Daksla,Ashley Wang,Zhaosheng Jin,Abhishek Gupta,Sergio D Bergese
DOI: https://doi.org/10.2147/DDDT.S372612
2023-03-23
Abstract:Neil Daksla, 1 Ashley Wang, 1 Zhaosheng Jin, 1 Abhishek Gupta, 1 Sergio D Bergese 1, 2 1 Department of Anesthesiology, Stony Brook University Health Science Center, Stony Brook, NY, 11794-8480, USA; 2 Department of Neurosurgery, Stony Brook University Health Science Center, Stony Brook, NY, 11794-8480, USA Correspondence: Sergio D Bergese, Department of Anesthesiology, Stony Brook University School of Medicine, Health Sciences Center, Level 4, Room 060, Stony Brook, NY, 11794, USA, Tel +1 631 444-2979, Fax +1 631 444-2907, Email Despite current advances in acute postoperative pain management, prevalence remains high. Inadequate treatment could lead to poor outcomes and even progression to chronic pain. Opioids have traditionally been the mainstay for treatment of moderate to severe acute pain. However, their use has been associated with opioid-related adverse events (ORAEs), such as respiratory depression, sedation, nausea, vomiting, pruritus, and decreased bowel motility. In addition, their liberal use has been implicated in the current opioid epidemic. As a result, there has been renewed interest in multimodal analgesia to target different mechanisms of action in order to achieve a synergistic effect and minimize opioid usage. Oliceridine is a novel mu-opioid receptor agonist that is part of a new class of biased ligands that selectively activate G-protein signaling and downregulate β-arrestin recruitment. Since G-protein signaling has been associated with analgesia while β-arrestin recruitment has been associated with ORAEs, there is potential for a wider therapeutic window. In this review, we will discuss the clinical evidence behind oliceridine and its potential role in acute postoperative pain management. We have systematically searched the PubMed database using the keywords oliceridine, olinvyk , and trv130 . All articles identified were reviewed and evaluated, and all clinical trials were included. Keywords: postoperative pain, opioids, multimodal analgesia, opioid-related adverse events, biased agonism Postoperative pain is one of the most common complaints following surgery. Despite current advances and a greater understanding of the various pain pathways, results from national surveys in the United States show that incidence could be as high as 86%. 1,2 A 2016 cross-sectional observational study including over 15,000 patients undergoing surgery in the United Kingdom revealed that 37.2% and 11.0% of patients reported moderate and severe pain at the surgical site, respectively, within 24 hours of their procedure. 3 Such results are also replicated around the world, such as in Germany, 4 Sweden, 5 Thailand, 6 and Kenya. 7 Postoperative pain management remains a common challenge in modern day medicine, and adverse outcomes of inadequate treatment have been well documented. Poorly controlled pain causes physiologic stress in the body that compromises various organ systems, resulting in adverse events ranging from myocardial ischemia and infarction, pulmonary infections, paralytic ileus, urinary retention, thromboembolism, and impaired immunity. 8 In addition, it also induces psychologic stress responses such as anxiety and fear—all of which lead to increased morbidity and mortality. 9 Undertreatment may also impair the rehabilitation process, prolong a patient's length of stay in the hospital, increase the risk of readmission, and increase the overall cost of care. 2,10 Finally, in certain cases, acute postoperative pain may even develop into persistent pain lasting more than 3–6 months after surgery in 10–50% of patients. 11 Opioid analgesia is considered the mainstay of postoperative pain management, including morphine, hydromorphone, and fentanyl. Opioids bind to receptors in the central nervous system and peripheral tissues. The three main types of opioid receptors are mu, delta, and kappa; all three are seven transmembrane G protein-coupled receptors (GPCRs). The binding of a ligand triggers conformational changes in the opioid receptor, which causes its C terminus to couple to the heterotrimeric G i protein. 12 When GTP is replaced by GDP at the G ɑ subunit, the trimeric G protein complex dissociates into G ɑ and G βγ subunits. The G ɑ subunit in turn inhibits adenylyl cyclase from producing cAMP, reduces the conductance of voltage-gated Ca 2+ channels, and opens inwardly rectifying K + (GIRK) channels to prevent neuronal excitation and stop the propagation of action potentials. In addition, the G βγ subunit activates the phospholipase C (PLC)/phosphokinase C (PKC) pathway to modulate Ca 2+ chann -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal